Botulinum toxin type A for facial rejuvenation - United States and United Kingdom perspectives

被引:50
|
作者
Lowe, NJ
机构
[1] Cranley Clin, London W1M 9AD, England
[2] Univ Calif Los Angeles, Sch Med, Dept Dermatol, Los Angeles, CA USA
[3] UCL, Sch Med, Dept Dermatol, London W1N 8AA, England
关键词
D O I
10.1111/j.1524-4725.1998.tb04100.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND. Botulinum A toxin has been well documented as a successful treatment for hyperfunctional upper facial expression lines. Currently, there are two commercial sources for botulinum toxin-Botox(R) and Dysport(R). Only Boton: is currently available in the United States; however, both Botox(R) and Dysport(R) are available in a number of European and other countries. OBJECTIVES. There are several differences between these two sources of botulinum toxin, including different potency of their dosage units. This article will review the uses of these two sources of botulinum toxin and discuss the dilution and dosing of botulinum toxin for facial expression lines. RESULTS. One unit of Botox(R) is approximately equivalent in potency to 4 LT of Dysport(R). CONCLUSIONS. Both commercial types of botulinum toxin can be used interchangeably with appropriate dosage selection. (C) 1998 by the American Society for Dermatologic Surgery, Inc.
引用
收藏
页码:1216 / 1218
页数:3
相关论文
共 50 条
  • [1] Botulinum Toxin in Facial Rejuvenation: An Update
    Carruthers, Jean
    Carruthers, Alastair
    [J]. OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2010, 37 (04) : 571 - +
  • [2] The efficacy of intradermal injection of type A botulinum toxin for facial rejuvenation
    Zhu, Jie
    Ji, Xi
    Xu, Yang
    Liu, Juan
    Miao, Ying-Ying
    Zhang, Jia-An
    Luo, Dan
    Zhou, Bing-Rong
    [J]. DERMATOLOGIC THERAPY, 2017, 30 (01)
  • [3] Botulinum Toxin in Facial Rejuvenation: An Update
    Carruthers, Jean
    Carruthers, Alastair
    [J]. DERMATOLOGIC CLINICS, 2009, 27 (04) : 417 - 425
  • [4] Botulinum Toxin Type A for Facial Rejuvenation: Treatment Evolution and Patient Satisfaction
    Ali Sepehr
    Nitin Chauhan
    Ashlin J. Alexander
    Peter A. Adamson
    [J]. Aesthetic Plastic Surgery, 2010, 34 : 583 - 586
  • [5] Botulinum Toxin Type A for Facial Rejuvenation: Treatment Evolution and Patient Satisfaction
    Sepehr, Ali
    Chauhan, Nitin
    Alexander, Ashlin J.
    Adamson, Peter A.
    [J]. AESTHETIC PLASTIC SURGERY, 2010, 34 (05) : 583 - 586
  • [6] Facial Rejuvenation After Intradermal Botulinum Toxin: Is it Really the Botulinum Toxin or is it the Pricks?
    Kapoor, Rinky
    Shome, Debraj
    Jain, Vandana
    Dikshit, Rajesh
    [J]. DERMATOLOGIC SURGERY, 2010, 36 (04) : 2098 - 2105
  • [7] Aesthetic Facial Botulinum Toxin Education - a Cross-Sectional Analysis of the United Kingdom (UK) Courses
    Zargaran, A.
    Mansour, H. Khademi
    Smith, K.
    Daneshi, K.
    Sousi, S.
    Zargaran, D.
    Davies, J.
    Woollard, A.
    Mosahebi, A.
    [J]. BRITISH JOURNAL OF SURGERY, 2024, 111
  • [8] Analysis of Botulinum Toxin Products and Litigation in the United States
    Korman, John B.
    Jalian, H. Ray
    Avram, Mathew M.
    [J]. DERMATOLOGIC SURGERY, 2013, 39 (11) : 1587 - 1591
  • [9] Complications with the use of botulinum toxin type a in facial rejuvenation: Report of 8 cases
    Ferreira, MC
    Salles, AG
    Gimenez, R
    Soares, MFD
    [J]. AESTHETIC PLASTIC SURGERY, 2004, 28 (06) : 441 - 444
  • [10] Combination therapy of botulinum toxin type A and hyaluronic acid filler for facial rejuvenation
    Zhang, Wei
    Xie, Yongjun
    Liu, Weihua
    Lei, Jing
    Liu, Yilun
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (05): : 5033 - 5038